MYRIAD GENETICS INC

Myriad Genetics announced the expanded availability of its Precise MRD™ test to include breast, colorectal, and renal cancers, significantly broadening access for over 6 million individuals in the U.S. The ultrasensitive, whole-genome sequencing-based assay tracks up to 1,000 variants per patient, providing dynamic insights into disease status. This expansion is supported by the publication of results from the MONITOR-Breast study, which demonstrated the test's clinical validity and ability to predict treatment response and identify at-risk patients with high accuracy.

Myriad Genetics, Inc. announced that Daniel M. Skovronsky, M.D., Ph.D., a member of its Board of Directors, resigned from his position, effective immediately on June 17, 2026. The company clarified that Dr. Skovronsky's departure was not a result of any disagreement with its operations, policies, or practices.

Myriad Genetics, Inc. stockholders approved an amendment to the 2012 Employee Stock Purchase Plan, increasing authorized shares by an additional 4,000,000. Stockholders also approved the 2026 Employee, Director and Consultant Equity Incentive Plan, which authorizes 8,463,567 shares, including shares rolled over from the 2017 Plan. Additionally, three Class III directors were elected, Ernst & Young LLP was ratified as the independent auditor, and the advisory vote on named executive officer compensation was approved.

Myriad Genetics, Inc. announced the appointment of Raj Jampa as Chief Technology Officer (CTO), effective June 1, 2026. Jampa will be responsible for the strategy and execution of Myriad's technology organization, with a focus on leveraging AI to enhance efficiency and effectiveness. CEO Sam Raha highlighted Jampa's proven leadership and experience in scaling businesses and accelerating technology innovation. Jampa's background includes senior technology roles at Agilent Technologies, Exact Sciences, and Genomic Health, where he led large-scale transformation initiatives.

Myriad Genetics announced it will share data demonstrating the utility of its Precise MRD™ (molecular residual disease) test across diverse cancer types through six poster presentations. Interim outcomes from the MONSTAR-SCREEN-3 study showed exceptional performance, with 97% baseline detection and 16% of samples detected in the ultrasensitive range. Importantly, post-surgical ctDNA positivity at one month was strongly prognostic for recurrence risk, indicating significantly worse disease-free survival. The company emphasizes the clear advantage of its whole-genome, personalized MRD approach in detecting clinically meaningful signals at very low ctDNA levels, potentially enabling earlier clinical decision-making.

Myriad Genetics announced the launch of its Prolaris + AI Test, a new prostate cancer biomarker test combining clinical-pathological features, a molecular score, and AI-powered digital pathology. This test aims to improve active surveillance planning by identifying patients safe for active surveillance and personalizing its intensity, addressing a critical gap in prostate cancer management. The AI metric will be available for U.S. Prolaris Biopsy Tests (excluding New York State) processed from May 29, 2026, with New York approval expected soon.

Myriad Genetics, Inc. announced a partnership with actress Jackie Tohn to raise awareness about the importance of hereditary cancer testing using its MyRisk ® Hereditary Cancer Test. Tohn shared her personal story of discovering a BRCA1 gene variant through testing, which led her to undergo prophylactic surgery. The campaign emphasizes early detection and personalized risk management for 11 cancer types, highlighting risk factors and the test's comprehensive assessment, particularly for individuals with family history or Ashkenazi Jewish ancestry.

Myriad Genetics announced that its management will participate in two upcoming healthcare conferences. The company will hold 1-to-1 investor meetings at the BofA Securities 2026 Health Care Conference on May 13, 2026. Additionally, Myriad management will conduct a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, which will be webcast live.

Myriad Genetics reported a significant increase in net loss for the first quarter of 2026, reaching $(34.1) million, compared to a net loss of $(0.1) million in the prior year period. This was partly due to a $4.5 million goodwill impairment charge. Despite a slight increase in total revenue to $200.4 million, the company's profitability declined, and its cash position decreased. The company also disclosed ongoing legal proceedings and plans for new equity incentive plans subject to stockholder approval.

Myriad Genetics reported first quarter 2026 financial results, with revenue increasing 2% year-over-year to $200.4 million. The company posted a GAAP net loss of $34.1 million, or $0.36 per share, and an adjusted loss per share of $0.09. Despite a decline in Prenatal Health, the Cancer Care Continuum and Mental Health segments showed strong growth, and the company reiterated its full-year 2026 financial guidance, reflecting ongoing progress and new product launches.